Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; GDNF therapy; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; MSC-NTF; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Preclinical Autistic disorder
  • No development reported Huntington's disease; Multiple sclerosis; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Huntington's-disease in Israel (Intrathecal, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (Intrathecal, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel (Intrathecal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top